Milberg has decades of experience investigating securities fraud claims and holding those who commit them accountable both in the United States and globally. Over 50 years ago, we pioneered the litigation of claims involving investment products, securities, and the banking industry with the use of class-action lawsuits. Our litigation set the standard for case theories, organization, discovery, methods of settlement, and amounts recovered for clients.
Milberg has served as Lead Counsel or Co-Lead Counsel in state and federal securities lawsuits that have returned billions of dollars to investors and prompted meaningful changes in corporate governance, including In re Merck & Co., Inc. Securities Litigation, In re Tyco International, Ltd. Securities Litigation, In re Nortel Networks Corp. Securities Litigation, and In re Lucent Technologies, Inc. Securities Litigation.
Calling on its long history of successfully handling complex securities disputes against the world’s most powerful companies, Milberg continues to aggressively pursue these cases on behalf of institutional and individual investors harmed by corporate fraud, breaches of fiduciary duty, and other financial wrongdoing.
As an example of our ongoing securities practice, in June 2019, Milberg filed a class-action lawsuit on behalf of holders of Bone Biologics Corporation (BBLG) common stock, alleging violations of Section 14(c) of the Securities Exchange Act of 1934 and Rule 14c-6, as well as other state law causes of action including breach of fiduciary duty by the BBLG’s directors and controlling stockholders, in connection with a change of control transaction.
Focus Areas of Practice:
- Fraudulent statements on corporate public filings
- Misappropriation of corporate funds
- Business metric manipulation
- Breaches of fiduciary duty
- Regulatory violations